Duloxetine Capsule, Delayed Release
Product Images NDC 68788-8623

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 68788-8623). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (69d6387b 794f 415d 8013 23cca0a6984f 01)

Chemical structure of duloxetine hydrochloride, showing a naphthalene ring connected to a thiophene ring with a chiral center and a side chain containing an amine group methylated and complexed with hydrochloride.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 02)

A Kaplan-Meier curve displaying the proportion of patients with relapse over time (days) comparing Duloxetine treatment with placebo. The graph shows time from randomization to relapse on the x-axis and the proportion of patients with relapse on the y-axis, with separate lines for Duloxetine and placebo groups.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 03)

A Kaplan-Meier curve chart comparing the proportion of patients with relapse over time (days) following randomization. The graph shows two lines representing treatment groups: Duloxetine and placebo. The vertical axis represents the proportion of patients with relapse, while the horizontal axis shows time from randomization to relapse in days.*

FDA Label Image

Figure 1 (69d6387b 794f 415d 8013 23cca0a6984f 04)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares four groups: Duloxetine 60 mg twice daily (BID), Duloxetine 60 mg once daily (QD), Duloxetine 20 mg QD, and placebo, showing trends of patient improvement across varying pain improvement percentages.*

FDA Label Image

Figure 2 (69d6387b 794f 415d 8013 23cca0a6984f 05)

A line graph depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and placebo, showing patient response percentages along the vertical axis and pain improvement percentages along the horizontal axis.*

FDA Label Image

Fig 5 (69d6387b 794f 415d 8013 23cca0a6984f 06)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo, illustrating trends in pain improvement for each group over increasing percentages of pain reduction.*

FDA Label Image

Fig 6 (69d6387b 794f 415d 8013 23cca0a6984f 07)

A line chart depicting the percentage of patients improved in relation to percent improvement in pain from baseline. It compares four groups: Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two curvilinear trends), and placebo. The x-axis represents percent improvement in pain from baseline from >0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%.*

FDA Label Image

Fig 7 (69d6387b 794f 415d 8013 23cca0a6984f 08)

A line graph showing the percentage of pediatric patients aged 13 to 17 with juvenile fibromyalgia syndrome who achieved various levels of pain relief at week 12 in Study FM-4. It compares Duloxetine 60 mg once daily versus placebo, plotting percent improvement in pain from baseline on the x-axis against the percentage of patients improved on the y-axis.*

FDA Label Image

Figure 8 (69d6387b 794f 415d 8013 23cca0a6984f 09)

A line chart comparing the percentage of patients improved between Duloxetine 60/120 mg once daily and placebo. The x-axis shows percent improvement in pain from baseline (BOCF), and the y-axis shows the percentage of patients improved, ranging from 0 to 100%. Duloxetine consistently shows higher patient improvement percentages than placebo across different pain improvement levels.*

FDA Label Image

Figure 9 (69d6387b 794f 415d 8013 23cca0a6984f 10)

A line graph comparing the percentage of patients improved with Duloxetine 60 mg once daily versus placebo across various levels of percent improvement in pain from baseline (BOCF). The x-axis shows percent improvement thresholds, while the y-axis shows the percentage of patients improved. Duloxetine shows higher patient improvement at most thresholds compared to placebo.*

FDA Label Image

Figure 10 (69d6387b 794f 415d 8013 23cca0a6984f 11)

A line graph comparing the percentage of patients improved with duloxetine 60/120 mg once daily versus placebo, plotted against percent improvement in pain from baseline (BOCF). The x-axis represents percent improvement in pain, and the y-axis shows the percentage of patients improved. Duloxetine shows higher patient improvement across pain improvement percentages compared to placebo.*

FDA Label Image

Duloxetine Delayed-release Cap Usp 60mg (69d6387b 794f 415d 8013 23cca0a6984f 15)

Label for Duloxetine Delayed-Release Capsules USP 60 mg, a generic for Cymbalta, manufactured by Lupin Limited and labeled by Preferred Pharmaceuticals Inc. The label includes dosage and storage instructions in English and Spanish, a barcode, and a caution against unauthorized drug transfer. The capsule is described as blue and green, imprinted with LU Q03.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.